Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared a post on X:
“COMy 2026, Evangelos Terpos summarizing one of the most practice-changing (even if niche) data I’ve seen for bone-modifying agents in myeloma.
For moderate CKD, consider denosumab 60 mg, not 120 mg, to lower hypoCa. Not randomized, but very reasonable given how severe hypoCa can be!”
Other articles featuring Rahul Banerjee on OncoDaily.